Paradigm Biopharmaceuticals (ASX:PAR) OCF Yield %: -27.98 (As of Jun. 27, 2026)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
28 GF Score
Price A$0.16
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals OCF Yield %?

Paradigm Biopharmaceuticals ASX:PAR -3.13% 28 OCF Yield % is -27.98 as of Jun. 27, 2026. GuruFocus rates ASX:PAR with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 1,419 Biotechnology companies, Paradigm Biopharmaceuticals ranks worse than 74.07% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Paradigm Biopharmaceuticals's Trailing 12-Month Cash Flow from Operations is A$-27.42 Mil, and Market Cap is A$90.93 Mil. Therefore, Paradigm Biopharmaceuticals's OCF Yield % for today is -27.98%.

The historical rank and industry rank for Paradigm Biopharmaceuticals's OCF Yield % or its related term are showing as below:

ASX:PAR' s OCF Yield % Range Over the Past 10 Years
Min: -27.98   Med: 0   Max: -27.98
Current: -27.98

During the past 10 years, the highest OCF Yield % of Paradigm Biopharmaceuticals was -27.98%. The lowest was -27.98%. And the median was %.

ASX:PAR's OCF Yield % is ranked worse than
74.07% of 1419 companies
in the Biotechnology industry
Industry Median: -8.48 vs ASX:PAR: -27.98

Paradigm Biopharmaceuticals's OCF Margin % for the quarter that ended in Dec. 2025 was %.

Paradigm Biopharmaceuticals OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Paradigm Biopharmaceuticals OCF Yield % Related Terms

Paradigm Biopharmaceuticals OCF Yield % Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals OCF Yield % Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.23 -14.34 -16.20 -73.81 -13.46

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.31 -33.40 -11.26 -13.09 -26.97

ASX:PAR vs VRTX, REGN, ALNY: OCF Yield % Comparison

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paradigm Biopharmaceuticals OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's OCF Yield % falls into.


ASX:PAR
28GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Paradigm Biopharmaceuticals's OCF Yield % for the fiscal year that ended in Jun. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-15.993 / 118.775845
=-13.46%

Paradigm Biopharmaceuticals's annualized OCF Yield % for the quarter that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-19.649 * 2 / 145.69646
=-26.97%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -27.98 mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a OCF Yield % of -27.98 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Paradigm Biopharmaceuticals and its competitors. According to the industry distribution chart, Paradigm Biopharmaceuticals ranks #1051 out of 1419 companies in the Biotechnology industry, placing it in the top 74.1%.
Is Paradigm Biopharmaceuticals' OCF Yield % too high?
Paradigm Biopharmaceuticals' current OCF Yield % is -27.98. Based on the distribution chart, Paradigm Biopharmaceuticals ranks #1051 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Paradigm Biopharmaceuticals ranks #1051 out of 1419 companies for OCF Yield %. This places Paradigm Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current OCF Yield % is -27.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current OCF Yield % of -27.98. The current OCF Yield % is -27.98. Paradigm Biopharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current OCF Yield % is -27.98 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
28GF Score

Get the complete analysis for ASX:PAR

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.16
Price